Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protalix Biotherapeutics Inc PLX

Healthcare Biotechnology
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the... see more

Recent & Breaking News (NYSEAM:PLX)

Protalix BioTherapeutics Reports Second Quarter 2022 Financial and Business Results

PR Newswire August 15, 2022

Protalix BioTherapeutics to Announce Second Quarter 2022 Financial and Business Results Conference Call on August 15, 2022

PR Newswire August 8, 2022

Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors

PR Newswire June 30, 2022

Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease

PR Newswire May 26, 2022

Protalix BioTherapeutics Reports First Quarter 2022 Financial and Business Results

PR Newswire May 16, 2022

Protalix BioTherapeutics to Announce First Quarter 2022 Financial and Business Results Conference Call on May 16, 2022

PR Newswire May 9, 2022

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease

PR Newswire April 4, 2022

Protalix BioTherapeutics Reports Fiscal Year 2021 Financial and Business Results

PR Newswire March 31, 2022

Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022

PR Newswire March 24, 2022

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease

PR Newswire March 18, 2022

Protalix BioTherapeutics to Participate in the 18th Annual WORLDSymposium(TM) 2022

PR Newswire February 3, 2022

Protalix BioTherapeutics Issues 2021 Letter to Stockholders

PR Newswire December 22, 2021

Protalix BioTherapeutics Reports Third Quarter 2021 Financial Results and Provides Financial and Business Update

PR Newswire November 15, 2021

Protalix BioTherapeutics to Release Third Quarter 2021 Financial Results and Provide a Financial and Business Update on November 15, 2021

PR Newswire November 8, 2021

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Dosing of Last Patient in Phase III BALANCE Clinical Trial PRX-102 for the Treatment of Fabry Disease

PR Newswire October 15, 2021

Protalix Biotherapeutics and Chiesi Global Rare Diseases Provide Regulatory Update on PRX-102 for the Treatment of Fabry Disease

PR Newswire October 11, 2021

Protalix BioTherapeutics Announces Closing of Private Note Exchange

PR Newswire August 26, 2021

Protalix BioTherapeutics Reports Second Quarter 2021 Financial Results and Financial and Business Update

PR Newswire August 16, 2021

Protalix BioTherapeutics Announces Private Note Exchange

PR Newswire August 13, 2021

Protalix BioTherapeutics to Release Second Quarter 2021 Financial Results and Provide a Financial and Business Update on August 16, 2021

PR Newswire August 9, 2021